Effect of Local Fibrinogen Administration on Postoperative Bleeding in Coronary Artery Bypass Graft Patients by Payani, Narges et al.
  Journal of Cellular & Molecular Anesthesia (JCMA)  
Vol 1, No 1,  Winter 2016 
23 
1. Anesthesiology Research Center, 
Shahid Beheshti University of Medical 
Sciences, Tehran, Iran 
2. Cardiovascular Research Center, 
Shahid Beheshti University of Medical 
Sciences, Tehran, Iran 
3. Immunology Department, School of 










Corresponding Author:  
Ali Dabbagh, MD; Anesthesiology 
Research Center, Shahid Beheshti 
University of Medical Sciences, 
Tehran, Iran. Tel: (+98) 21-2243 
2572;  
Email: alidabbagh@yahoo.com 
Received: November 25. 2015 
Accepted: December 10, 2015 
Original Article  
 
 
Effect of Local Fibrinogen Administration on Postoperative 
Bleeding in Coronary Artery Bypass Graft Patients 
 
 
Narges Payani1, Mahnoosh Foroughi2, Abdolhamid Bagheri2, Samira Rajaei3, Ali Dabbagh1*  
 
Abstract 
Background: There are always concerns regarding postoperative bleeding in 
coronary artery bypass graft (CABG) patients; several different strategies 
have been used to compensate for it and to reduce the amount of blood 
transfusion. We designed this study to investigate local fibrinogen conditions 
in postoperative bleeding in adult patients undergoing CABG.  
Materials and Methods: In a double-blind clinical trial, after matching the 
inclusion and exclusion criteria, 50 patients entered the study. Pre- and 
postoperative data, including clinical and laboratory variables were assessed. 
Among them, preoperative and postoperative fibrinogen levels were 
measured. One group received 1g fibrinogen as a 50mL solution flushed over 
the epicardium before sternal closure; the other received 50mL normal saline 
as a placebo in the same method.  
Results: No difference between the two groups regarding preoperative and 
postoperative fibrinogen levels. Also, the two groups were the same 
regarding PT, PTT, INR, and platelet. However, bleeding was less and 
hematocrit level was higher in the local fibrinogen group.  
Conclusion: Local fibrinogen could decrease postoperative bleeding in 
CABG patients leading to decreased need for blood transfusion. 
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Introduction 
Cardiovascular diseases are among the main topics 
imposing a great burden of disease; ischemic heart 
diseases being one of the leading topics. Each year, 
many patients with ischemic heart disease undergo 
coronary artery bypass graft (CABG) surgery to treat 
their ischemic heart disease. However, there are some 
postoperative complications in CABG patients, 
postoperative bleeding is one of them. In the current 
era, to avoid the administration of blood products, 
several different agents have been used, both topically 
and intravenously (1-3). 
Fibrinogen is a multifunctional plasma protein 
that is a key protein in the coagulation cascade. 
Before being activated, fibrinogen is soluble; while it 
is changed to fibrin, it becomes insoluble and with 
help of platelets, forms a fibrin clot. As a matter of 
fact, in the pre-final step, change from fibrinogen to 
fibrin needs to yield the final product (4). 
Often, fibrinogen as a single product is used in 
patients with selective fibrinogen deficiency; 
however, usually, there are different degrees of 
impaired coagulation disorders in patients after 
cardiac surgery, during the post bypass period. 
Fibrinogen is among the first factors which would be 
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compromised (5-8). 
This study assessed the effect of local 
fibrinogen on the amount of postoperative bleeding, 
the need for blood transfusion, and lab tests of 
coagulation in adult patients undergoing CABG to 
compare the results with local placebo. 
 
Methods 
The study was approved by institutional review board 
(IRB) committees, Shahid Beheshti University of 
Medical Sciences, Tehran, Iran, regarding ethical and 
research considerations. Also, the study was 
registered and approved in the IRCT.ir with this code: 
IRCT201510222804N9. In a double-blind 
randomized clinical trial, all the patients admitted in 
the cardiac surgery operation room of a tertiary 
university hospital undergoing the first-time CABG 
entered the study. 
By using a randomization table, the patients 
were randomized into the two groups of study. Just a 
constant surgeon was considered as the study surgeon 
to assimilate the patients as much as possible between 
the two groups. 
The patients entered the study after matching 
the inclusion and exclusion criteria: 
Inclusion criteria were: 
 Age 40-75 
 Elective CABG with cardiopulmonary bypass 
(CPB) 
 Constant surgeon 
 Informed written consent  
The following conditions were considered as 
exclusion criteria: 
 Emergent or urgent surgery 
 Diabetes mellitus (or any of its complications like 
diabetic ketoacidosis or non-ketonic hyperosmolar 
diabetic coma) 
 Any previous history of stroke or underlying 
cerebral vascular disease 
 History of deep vein thrombosis 
 History of underlying hematologic disorders 
 Any carotid plaque creating significant stenosis 
(stenosis > 75%) 
 Underlying pulmonary disorders affecting the 
spirometry indices significantly (>50% decrease) 
 Acute renal failure 
 Chronic kidney disease leading to serum 
Cr>2mg/dL 
 Hepatic failure causing liver function test failure 
(>3 times than normal) 
 Off-pump CABG 
 Any unwanted complication in the operation 
period 
 Re-starting CPB after weaning from bypass 
 Pulmonary artery pressure >30 before the 
operation  
 Ejection fraction<30% 
 Congestive heart failure 
The patients were operated on with CPB and 
then, after weaning from bypass and administration of 
protamine, one of the two following approaches was 
used and after that, the sternum was closed and wired 
with steel wires: 
In the fibrinogen group, a solution including 1g 
of fibrinogen in 50mL volume was flushed over the 
epicardium just before sternal closure, and in the 
placebo group, 50 mL of normal saline solution is 
flushed to the same place.  
Then, the patients were transferred to the 
cardiac intensive care unit to pass their normal course 
of postoperative care. 
 The patients were controlled regarding the 
following variable demographic data 
 Preoperative and postoperative fibrinogen levels in 
fibrinogen group 
 Chest tube drainage at 3, 12, and 24 hours after the 
operation 
 Need for transfusion of blood products 
 preoperative and postoperative assessment of 
hemoglobin and platelet count 
 Coagulation lab tests, both preoperative and 
postoperative, including PT, PTT, and INR. 
 
Results 
The results of this study demonstrated that the two 
groups were similar regarding age (59.5±9.2 in 
fibrinogen group vs. 63.3±8.4 in the control group; p 
value=0.17) and also, regarding weight (73.1±11.8 in 
fibrinogen group vs. 73±7.8 in the control group; p 
value=0.99). The majority of patients were male; 
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however, there was no difference between the two 
groups regarding gender (Table 1). The amount of 
chest tube blood drainage was significantly lower in 
the fibrinogen group in 3, 12, and 24 hours after the 
operation (Table 2). 
On the other hand, the results of 5 other 
hematologic variables (PT, PTT, INR, hematocrit, and 
platelet) were measured (Table 3). Each of these 
variables was compared between the two groups 
before and after surgery.  
The final results demonstrated no difference 
between the two groups regarding all these variables 
except for one occasion: only hematocrit level after 
surgery was higher significantly in the fibrinogen 
group which could be due to less bleeding in this 
group and could be in concordance with the results of 
chest tube blood drainage. 
 
Discussion 
The results of this study demonstrated that local 
fibrinogen could decrease the amount of postoperative 
bleeding after CABG in adult patients. Also, topical 
fibrinogen could improve some of the parameters in 
the coagulation lab tests in these patients. It seems 
that topical fibrinogen has been able to activate local 
mechanisms of coagulation; possibly without 
activating systemic coagulation cascade, based on the 
results of fibrinogen levels in the two study groups 
postoperatively. In other words, local fibrinogen 
could improve postoperative bleeding in these 
patients and decrease the amount of bleeding when 
added as a topical flush; possibly because it improves 
local clot or local coagulation process. 
Postoperative bleeding is a major concern after 
cardiac surgery; many factors predispose these 
patients to bleed including high heparin dose 
administration throughout the cardiopulmonary 
bypass and also, the inflammatory process imposed 
by the bypass circuit; also, major shifts in blood 
components are among the other inevitable factors 
predisposing these patients to bleed. Some different 
preventive and therapeutic strategies have been 
proposed to resolve this problem; for example 
administration of anti-fibrinolytic agents like 
tranexamic acid and ɛ-Aminocaproic acid or selective 
coagulation factor administration though none have 
been fully effective (9). Another study also 
demonstrated that plasma fibrinogen level drops after 
cardiac surgery (10). Systemic administration of 
fibrinogen in some patients has been tried with its 
potential side effects. However, topical fibrinogen 
alone has not been used yet; while the combination of 
topical fibrinogen–thrombin patch (TachoSil®) has 
been tried with relatively satisfactory results in some 
surgeries (11-13). In a systematic review, the effects 
of TachoSil were assessed based on previous studies 
and it was demonstrated to be effective in thoracic, 
urology, and liver surgeries; however, this study did 
not include cardiac surgeries (9). In another study, 
TachoSil did not demonstrate any benefit compared to 
conventional therapies in cardiac surgeries regarding 
bleeding and blood requirements (11). On the other 
hand, human Fibrin Glue which is composed of 
fibrinogen, factor XIII, fibronectin, and thrombin has 
been demonstrated to be effective in controlling 
Table 2: Chest tube drainage in the two groups in mL 
 





3 hours after operation 42.5±104 135±112.5 0.009 
12 hours after operation 105±114.6 317±136 0.0001 
24 hours after operation 200±176.2 482.5±113.9 0.0001 
 
 







Male 10 15 0.10 
Female 12 13 
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bleeding in inguinal hernia repair, in a study that used 
Human Fibrin Glue in patients with underlying 
coagulation abnormalities; the results of the latter 
study using Human Fibrin Glue are somewhat similar 
to the results of our study (12). 
In two other studies, prophylactic fibrinogen 
was used in CABG. In one study, which was a 
prospective randomized pilot study, the main research 
outcome was to assess the effect of prophylactic 
fibrinogen infusion on bleeding after CABG and 
demonstrated that preoperative fibrinogen concentrate 
infusion could decrease the amount of postoperative 
bleeding in CABG patients and increase postoperative 
hematocrit level; while there was no evidence of 
postoperative hypercoagulability or any significant 
effect on postoperative coagulation profile which was 
assessed by thromboelastography (14). Our study is 
different from this research because we have used 
local fibrinogen and also, the results of our study did 
not demonstrate an increased level of plasma 
fibrinogen in the postoperative period. 
In the other study, the main study outcome was 
to assess the effects of fibrinogen on biomarkers of 
coagulation, fibrinolysis, and platelet function, this 
study demonstrated that administration of systemic 
fibrinogen as a prophylactic agent in patients 
undergoing CABG has “no or minimal changes in 
biomarkers reflecting coagulation and platelet 
function” (15). Again, our study is different from the 
latter study because of using local fibrinogen and 
improved blood needs in the postoperative period; 
however, our results were similar since the results of 
our study did not demonstrate an improved 
coagulation profile in the lab tests during the 
postoperative period. 
Our study had several limitations: 
 We did not use thromboelastography while it 
could help us assess the coagulation profile better 
than our tests 
 We did not assess other coagulation factors while 
they could be affected or could be different in the two 
groups; 
 We did not assess platelet function in the 
postoperative period while it could be different in the 
two groups. 
 However, we did not assay the above variables 
and these could be drawbacks in the study. 
 
Table 3: PT, PTT, INR, Hematocrit and Platelet in the two groups in before and after the operation. 
 





PT (before surgery) 13.4±4 12.6±0.7 0.41 
PT (after surgery) 15.1±5.3 13.3±1.5 0.15 
PTT (before surgery) 33.4±7.1 36.8±16 0.39 
PTT (after surgery) 40.1±16.6 38±7.2 0.61 
INR (before surgery) 1.2±0.22 1.1±0.15 0.37 
INR (after surgery) 1.3±0.28 1.2±0.14 0.25 
Hematocrit (before surgery) 43.3±3.4 44.2±2.2 0.32 
Hematocrit (after surgery) 37.1±6 32.5±3.3 0.004 
Platelet (×103) (before surgery) 254.2±69.4 237.5±47 0.11 
Platelet (×103) (after surgery) 205±50.3 192.6±50.4 0.44 
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Conclusion 
Our study demonstrated that adding local fibrinogen 
could decrease postoperative bleeding and decrease 
the need for blood products, while postoperative 
hematocrit level was higher in the local fibrinogen 
group. Meanwhile, there was no increase in the 
postoperative level of plasma fibrinogen; suggesting a 
possible effect of local fibrinogen in improving local 
clotting mechanisms without a significant rise in 
plasma fibrinogen. The latter is important because in 
coronary patients we are worried about increased 
coagulation status especially in the new coronary 
grafts in the postoperative period. 
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